Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: Kevin Podsiadlik who wrote (2796)	8/4/1999 12:50:00 AM
From: out_of_the_loop	Read Replies (2) \| Respond to of 10293

Kevin: The first clinicals have been done a long time and were sent to the NEJM several months ago. That is what Dan's post that you referenced was about. They tested people with cold symptoms double blind and gave them Zicam. The study is not public yet because it is pending at the NEJM. It was reviewed for a Detroit TV segment prior to that by Dr. Seidman of Wayne State/Henry Ford. I have mentioned this several times, including that his videotape from Detroit Channel 7 is still on the net. Dan's post was and is still entirely true. The second clinicals are presently underway in several test sites and will be sent to a medical journal (not necessarily the NEJM -that would indeed be premature) when they are finished, collated and written up. They involve exposing people to a known strain of rhinovirus then double blinded treatment with placebo or Zicam. There is also an allergy segment to the studies. All this material is in the recent press releases. All one has to do is read it carefully. Nothing strange, extraordinary or fishy. Regards, Howard